Enantiopure terphenyls with two ortho-atropisomeric axes
US-11434253-B2 · Sep 6, 2022 · US
Crystalline ligand
US10077281B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10077281-B2 |
| Application number | US-201615564338-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 15, 2016 |
| Priority date | Jun 19, 2015 |
| Publication date | Sep 18, 2018 |
| Grant date | Sep 18, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A ligand crystal structure of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bisdibenzo[d,f][1,3,2]-dioxaphosphepin. Formule (I)
First claim
Opening claim text (preview).
What is claimed is: 1. A crystalline form of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bisdibenzo[d,f][1,3,2]-dioxaphosphepin, which displays its two strongest reflections, stated as 2Θ values, at 7.8±0.2° and 19.7±0.2° in an X-ray powder diffractogram, measured at 25° C. with Cu-Kα radiation. 2. The crystalline form of claim 1 wherein the diffractogram displays at least 3 of the following reflections: # 2θ Angle (°) 1 8.3 ± 0.2 2 9.9 ± 0.2 3 10.9 ± 0.2 4 12.6 ± 0.2 5 13.8 ± 0.2 6 14.3 ± 0.2 7 15.1 ± 0.2 8 15.7 ± 0.2 9 16.1 ± 0.2 3. The crystalline form of claim 1 that is solvent-free. 4. The crystalline form of claim 1 lacking a significant reflection at 8.5±0.2° 2θ in an X-ray powder diffractogram, measured at 25° C. with Cu-Kα radiation. 5. The crystalline form of claim 1 having a melting point of 202-208° C., as determined by DSC. 6. The crystalline form of claim 5 having a DSC plot that exhibits an initial endothermic transition with a peak at 206° C. 7. The crystalline form of claim 1 having the XRD diffractogram of FIG. 2 . 8. The crystalline form of claim 1 having the TGA plot of FIG. 9 line B.
Assignees
Inventors
Classifications
- B01J31/2419Primary
comprising P as ring member · CPC title
- C07F9/65746Primary
the molecule containing more than one cyclic phosphorus atom · CPC title
condensed with carbocyclic or heterocyclic rings or ring systems · CPC title
Operations & Transport · mapped topic
characterised by their crystalline properties, e.g. semi-crystalline (catalysts comprising carbon B01J21/18; molecular sieves B01J29/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10077281B2 cover?
- A ligand crystal structure of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bisdibenzo[d,f][1,3,2]-dioxaphosphepin. Formule (I)
- Who is the assignee on this patent?
- Dow Technology Investments Llc
- What technology area does this patent fall under?
- Primary CPC classification B01J31/2419. Mapped technology areas include Operations & Transport.
- When was this patent published?
- Publication date Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).